Identification of Amiodarone Metabolites in Human Bile by Ultraperformance Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry
Open Access
- 11 March 2011
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 39 (6), 1058-1069
- https://doi.org/10.1124/dmd.110.037671
Abstract
Amiodarone is recognized as an effective drug in the treatment of arrhythmias. Previous experiments demonstrated that mono-N-desethylamiodarone (MDEA) was the major circulating metabolite in humans. In addition, dealkylation, hydroxylation, and deamination were minor metabolic pathways. The purpose of this study was to identify the metabolites of amiodarone in the bile obtained from patients with T-tube drainage after oral drug administration. Amiodarone metabolism in vitro was also investigated using human liver microsomes (HLMs) and S9 fraction. Ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-Q/TOF MS) revealed 33 metabolites in human bile, including 22 phase I and 11 phase II metabolites. The major metabolites were MDEA (M7) and ω-carboxylate amiodarone (M12). Metabolite M12 was isolated from human bile, and the chemical structure was confirmed using UPLC-Q/TOF MS and 1H NMR. Moreover, the authentic standards of two hydroxylated metabolites, 2-hydroxylamiodarone and 3′-hydroxylamiodarone, were obtained through microbial transformation. Several novel metabolic pathways of amiodarone in human were proposed, including ω-carboxylation, deiodination, and glucuronidation. The in vitro study demonstrated that incubation of HLMs with amiodarone did not give rise to any carboxyl metabolites. In contrast, M12 and its metabolites were detected in human liver S9 incubation samples, and the production of these metabolites were inhibited almost completely by 4-methylpyrazole, an inhibitor of alcohol dehydrogenase, suggesting the involvement of alcohol dehydrogenase in the ω-carboxylation of amiodarone. Overall, UPLC-Q/TOF MS analysis leads to the discovery of several novel amiodarone metabolites in human bile and underscores the importance of bile as an excretion pathway.Keywords
This publication has 21 references indexed in Scilit:
- Methods To Evaluate Biliary Excretion of Drugs in Humans: An Updated ReviewMolecular Pharmaceutics, 2006
- The Various Effects of Amiodarone on Thyroid FunctionThyroid®, 2001
- Interaction Between Amiodarone and LidocaineJournal of Cardiovascular Pharmacology, 1996
- Pharmacokinetics of amiodarone: Implications for drug therapyThe American Journal of Cardiology, 1993
- Study on the metabolism of racemic prolintane and its optically pure enantiomersXenobiotica, 1992
- Pharmacology and Pharmacokinetics of AmiodaroneThe Journal of Clinical Pharmacology, 1991
- Identification of metabolites of the 1″,1″-dimethylheptyl analogue of cannabidiol in rat and dogin vivXenobiotica, 1990
- Radioactive iodine thyroid uptake in patients with amiodarone-iodine-induced thyroid dysfunctionActa Endocrinologica, 1988
- Clinical Pharmacokinetics of AmiodaroneClinical Pharmacokinetics, 1984
- Renal elimination of amiodarone and its desethyl metabolitePostgraduate Medical Journal, 1983